Innovation news

<p>This TECNIO seal recognises the IRB Barcelona's Innovation department as a competitive agent in Catalonia’s innovation system</p>
24 Apr 2017

ACCIÓ awards the Institute’s Innovation Department with the quality seal TECNIO and two VALUNI grants for technology transfer projects

<p>Participants in the IV National Congress of Entrepreneurial Scientists in Barcelona. From left to right, Iliana López, Daniela Kalafatovic, Anna Bellmunt, Alba Olivares, Saska Ivanova, Sanja Zivanovic, Gonzalo Fernández-Miranda.</p>
11 Apr 2017

An innovative programme from IRB Barcelona’s Innovation Department enables researchers to explore how to implement their entrepreneurial ideas

<p>Albert Farré thinks that all young scientists are potentially fit for industry</p>
11 Apr 2017

How do you make a successful move from academia to industry? In March, Albert Farré, Brand Manager at Novartis Oncology, told IRB Barcelona scientists who attended the “Building Bridges in your network” workshop how he did it. And he has some good advice for budding entrepreneurs.

<p>BIO-Europe Spring is the premier springtime partnering conference for the biotechnology industry. Image: BIOCAT, "Fundació BioRegió de Catalunya” (BioRegion of Catalonia Foundation).</p>
21 Mar 2017

On the occasion of the BIO-Europe Spring 2017 event in Barcelona, the newspaper “La Vanguardia” has published an article about the campaign to host the new headquarters of the London-based European Medicines Agency (EMA) after Brexit. 

The article also includes a reference to the participation of IRB Barcelona’s Innovation Department in this three-day partnering conference for the biotechnology industry.

More information about IRB Barcelona’s participation

<p>IRB Barcelona's Innovation team strengthens ties with industry.</p>
20 Mar 2017

The 11th international partnering conference comes to Barcelona from 20 to 22 March.

19 young researchers at IRB Barcelona will also be attending the three-day conference.

BIO-Europe Spring is the premier springtime partnering conference for the biotechnology industry.

<p>The image shows tumour cells infected by the virus, which expresses a fluorescent protein. Over the days (in the image fifth day), the virus multiplies, generating new virions that infect more cancer cells (IDIBAPS, IRB Barcelona)</p>
16 Mar 2017

IDIBAPS and IRB Barcelona researchers show the effectiveness of a new strategy to achieved genetically modified viruses that infect only tumor cells, thus preserving healthy tissues.

It is an innovative approach that exploits the different expression profiles of certain proteins between tumor and healthy cells, thus allowing the virus to infect only the former.

 

<p>Scheme of therapeutic concept designed by IRB Barcelona. The protein frataxina binds to peptide shuttle (blue), allowing the protein to cross the blood brain barrier and reach the brain (IRB Barcelona)</p>
14 Mar 2017

IRB Barcelona starts a project with the long-term goal to achieve an injectable frataxin treatment able to reach the brain.

Frataxin is the protein that is reduced in those affected by this rare and degenerative disease, which has no cure.

The patients’ associations Babel Family and ASOGAF in Granada provide the funding for the initial 18 months of this challenge.

<p>Merus N.V. is a clinical-stage immuno-oncology company developing innovative bispecific antibody therapeutics.</p>
9 Feb 2017

The research collaboration will combine Merus’ Biclonics technology platform and unique cell and animal models at the Colorectal Cancer Laboratory led by Eduard Batlle to investigate the stroma.

7 Feb 2017

 

Last year, CERCA, the Catalan Government institution that supervises, supports and facilitates the activities of research of research centres in Catalonia, set up a patent fund called Gínjol. This initiative aims to provide funding for knowledge transfer projects and to promote the regional economy.

According to CERCA Director Lluís Rovira, “the idea is not to increase the number of patents, but rather choose those that can really have a commercial impact, with subsequent profits.” Eleven scientific institutions contributed resources to the...

31 Jan 2017

Patrick Aloy, ICREA researcher at IRB Barcelona, has told the programme 'L'Entrevista', broadcasted by “La Xarxa Televisió”, that research into Alzheimer’s disease is still unravelling the disease, how it starts and what would be a suitable approach to tackle it."

Because of the complexity of this condition, Aloy says, "we will not cure Alzheimer’s disease. We have to focus on halting its progression. The earlier we stop the development of this condition, the greater the improvement in the health of those who suffer from it."

"To halt its progression, we will be able to administer drugs when symptoms of the disease are detected, thereby...